Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Burkitt Lymphoma 25Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Recurrence 8Immunoglobulin Light-chain Amyloidosis 8Vomiting 7Nausea 7Lymphoma, Mantle-Cell 7Leukemia, Biphenotypic, Acute 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Leukemia 5Hodgkin Disease 5Smoldering Multiple Myeloma 4Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Lung Neoplasms 4Breast Neoplasms 4Blast Crisis 4Prostatic Neoplasms 3Plasmacytoma 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

venetoclax 6fludarabine phosphate 5Dexamethasone 4ibrutinib 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3pomalidomide 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2pirtobrutinib 1pembrolizumab 1obinutuzumab 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carmustine, poliferprosan 20 drug combination 1auricularum 1acalabrutinib 1Sirolimus 1RG7388 1Nivolumab 1Maintenance 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chromosome 17 deletion × dexamethasone acetate × Clear all
NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
33 enrolled 26 charts
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡